Dr Lisa Holland
Contact information
Lisa Holland
PhD
Research Facilitator
Lisa is Research Facilitator for the Mexico City Prospective Study – a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
She joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2006 as a member of the Vascular Overviews Group. Lisa worked on the meta-analyses of clinical trials of statins (Cholesterol Treatment Trialists Collaboration), of non-steroidal anti-inflammatory drugs (Coxib and NSAID Trialists Collaboration), and of angiotension receptor blockers for the treatment of Marfan Syndrom.
Lisa Holland completed an undergraduate degree in Biochemistry with Microbiology at Lancaster University and a PhD in Molecular Microbiology at the University of Nottingham.
Recent publications
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
-
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
-
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Journal article
Pitcher A. et al, (2022), Lancet
-
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
Journal article
BAIGENT C. et al, (2022), The Lancet
-
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials